Antimicrotubule Agents

Vinca alkaloids, taxanes, nab-paclitaxel, cabazitaxel, and ixabepilone

ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine  ·  ALL = acute lymphoblastic leukemia  ·  CRPC = castration-resistant prostate cancer  ·  CYP = cytochrome P450  ·  GTP = guanosine triphosphate  ·  IT = intrathecal  ·  NSCLC = non-small cell lung cancer  ·  PgP = P-glycoprotein  ·  PVC = polyvinyl chloride  ·  SAC = spindle assembly checkpoint  ·  SIADH = syndrome of inappropriate antidiuretic hormone secretion

Vinca Alkaloids vs Taxanes: Opposing Mechanisms, Same Endpoint
Feature Vinca Alkaloids Taxanes
Binding site Vinca domain on beta-tubulin (plus end) Taxane domain on beta-tubulin (interior lumen)
Effect on microtubules Suppress dynamic instability → depolymerization at high dose Stabilize polymer → prevent depolymerization
Net result SAC activation → sustained mitotic arrest → apoptosis (M-phase specific)
Resistance via PgP Yes — vincristine, vinblastine are PgP substrates Yes — paclitaxel, docetaxel are PgP substrates; cabazitaxel has low PgP affinity
Vinca Alkaloids: Key Differences
Vinca Alkaloid
Vincristine
  • Dose-limiting toxicity: peripheral neuropathy (not myelosuppression)
  • Neuropathy: length-dependent, begins with loss of ankle reflex
  • Autonomic: constipation, urinary retention
  • SIADH: hyponatremia, euvolemia, concentrated urine
  • CYP3A4 substrate: azoles increase exposure and neuropathy
  • Indications: ALL, lymphoma, Wilms tumor
Vinca Alkaloid
Vinblastine
  • Dose-limiting toxicity: myelosuppression (neutropenia, nadir 7–14 days)
  • Less neurotoxic than vincristine at equipotent doses
  • Vesicant: extravasation → hyaluronidase + warm compress
  • Hepatic clearance: CYP3A4; dose reduce in hepatic impairment
  • Indications: ABVD (Hodgkin lymphoma), testicular cancer
Vinca Alkaloid
Vinorelbine
  • Selectivity for mitotic over axonal microtubules → intermediate neurotoxicity
  • Dose-limiting toxicity: neutropenia
  • Available IV and oral (bioavailability ~43%)
  • Indications: NSCLC, breast cancer, cervical cancer
Taxanes: Vehicle, Premedication, and Key Differences
Taxane
Paclitaxel (Cremophor EL)
  • Premedication required: dexamethasone 20 mg (12h + 6h before) + diphenhydramine + H2 antagonist (30 min before)
  • Non-PVC tubing required (Cremophor leaches DEHP)
  • Metabolism: CYP2C8 (primary), CYP3A4
  • Dose-limiting acute toxicity: neutropenia (nadir 8–11 days)
  • Dose-limiting cumulative toxicity: sensory neuropathy
Taxane
Docetaxel (Polysorbate 80)
  • Premedication: dexamethasone 8 mg twice daily ×3 days (starting day before) → reduces fluid retention and hypersensitivity
  • Cumulative fluid retention: edema, pleural effusions (above 400 mg/m²)
  • More severe myelosuppression than paclitaxel
  • Nail toxicity and skin erythema more prominent
  • Metabolism: CYP3A4 (predominant)
Taxane Variants
Nab-Paclitaxel & Cabazitaxel
  • Nab-paclitaxel: albumin-bound, no Cremophor EL, no premedication, no PVC tubing required; neuropathy still prominent
  • Nab-paclitaxel indications: breast, NSCLC (+ carboplatin), pancreatic (+ gemcitabine)
  • Cabazitaxel: low PgP affinity → active in docetaxel-resistant CRPC
  • Cabazitaxel: high febrile neutropenia rate; G-CSF prophylaxis mandatory
Intrathecal Vinca Alkaloid: Four Non-Negotiable Safeguards
(1) Vinca alkaloids dispensed only in minibags — never syringes. (2) Every container labeled: For Intravenous Use Only — Fatal If Given By Other Routes. (3) Every minibag sealed in outer overpacking bag with same warning. (4) IT chemotherapy prepared, transported, and administered in separate time and location from IV vinca alkaloids — never simultaneously in the same space. Violation of any safeguard has caused patient deaths.